Recently, a neuroprotective role for B2R was highlighted, and the use of B2R agonists was proposed as a possible therapeutic option for patients diagnosed with Alzheimer’s disease [64]. This evidence concerns the gene BDKRB2 and early-onset autosomal dominant Alzheimer disease.